Pulmonary arterial hypertensionNews & Research
17 curated articles for Pulmonary arterial hypertension — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Pflugers Archiv : European journal of physiology May 2, 2026
The role of IP 3 R and TRPC3 channels in vasoconstriction and hypertension.
Hypertension is a major global health concern and a leading risk factor for cardiovascular diseases, including stroke, myocardial infarction, and heart failure. A hallmark of hypertension is elevated total peripheral vascular resistance, often driven by sustained and abnormal vasoconstriction. Calci...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension that may be relevant for patients and caregivers.
- International immunopharmacology May 2, 2026
Inflachromene attenuates monocrotaline-induced pulmonary arterial hypertension by suppressing the HMGB1-TLR4/RAGE-NF-κB signaling pathway.
Pulmonary arterial hypertension (PAH) is a debilitating and fatal cardiovascular disorder marked by progressive deterioration of pulmonary arterial function, mainly due to structural remodeling. This pathological remodeling is predominantly driven by prolonged inflammatory activity together with dys...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension that may be relevant for patients and caregivers.
- Cardiovascular research Apr 28, 2026
Dysregulated Klotho and FGF23 signalling aggravates vascular remodelling in age-related pulmonary hypertension.
Pulmonary arterial hypertension (PAH) is a chronic condition of elevated pulmonary arterial pressure caused by vascular remodelling due to increased proliferation of pulmonary arterial smooth muscle cells (PASMC). Initially described as a disease primarily affecting young women, it now increasingly ...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension that may be relevant for patients and caregivers.
- The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation Apr 22, 2026
First longitudinal spatial transcriptomics analysis in pulmonary arterial hypertension.
First longitudinal spatial transcriptomics analysis in pulmonary arterial hypertension.
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension that may be relevant for patients and caregivers.
- Future cardiology Apr 20, 2026
Evaluating sotatercept in the treatment of pulmonary arterial hypertension.
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by pulmonary vascular remodeling, right ventricular overload, and premature death. Despite advances achieved through endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, and prostacyclin analogs, these agen...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension that may be relevant for patients and caregivers.
- Respiratory research Apr 11, 2026
Update on pulmonary hypertension.
The hemodynamic definition of pulmonary hypertension including a mean pulmonary arterial pressure > 20 mmHg is evidence based, but the threshold of 15 mmHg for the pulmonary arterial wedge pressure, deciding between pre-and postcapillary PH, is not. Indeed, based on the mo...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension that may be relevant for patients and caregivers.
- Journal of hypertension Mar 25, 2026
Targeting the Hippo pathway in pulmonary arterial hypertension: emerging pharmacological strategies.
Pulmonary arterial hypertension (PAH) is a severe, progressive disease characterized by pulmonary vascular remodeling and increased resistance, ultimately leading to right heart failure and high mortality. The Hippo signaling pathway has emerged as a key regulator of PAH development by influencing c...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension that may be relevant for patients and caregivers.
- Journal of the American College of Cardiology Mar 11, 2026
Pulmonary Hypertension Associated With Left Heart Disease: Challenges, Emerging Strategies, and Future Directions.
Pulmonary hypertension (PH) associated with left heart disease (LHD) is the most prevalent form of PH and is associated with substantial morbidity and mortality risk. Diagnosis is challenging because of overlapping phenotypes, imprecise echocardiographic estimates, and reliance on invasive hemodynam...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension that may be relevant for patients and caregivers.
- European heart journal Mar 8, 2026
EP4/ANXA2 axis in pulmonary arterial hypertension: therapeutic implications.
Pulmonary arterial hypertension (PAH) is a progressive condition marked by the abnormal proliferation of pulmonary artery smooth muscle cells (PASMCs), leading to significant remodelling of the pulmonary arteries (PAs). The cyclooxygenase metabolite of arachidonic acid prostaglandin E2 and its recep...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension that may be relevant for patients and caregivers.
- Pediatric cardiology Mar 5, 2026
Macitentan in Children with Pulmonary Arterial Hypertension: A Multicenter Experience.
Macitentan seems to improve outcomes in patients with pulmonary arterial hypertension (PAH). Nevertheless, safety and efficacy in pediatric patients is still to be determined. Multi-center, observational study to assess safety and efficacy of oral macitentan in patients under 18 years-of-age fr...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension that may be relevant for patients and caregivers.
- European journal of internal medicine Feb 18, 2026
Sotatercept for pulmonary arterial hypertension.
Sotatercept for pulmonary arterial hypertension.
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension that may be relevant for patients and caregivers.
- Journal of molecular and cellular cardiology Feb 2, 2026
Extracellular-cAMP suppresses pulmonary arterial hypertension-induced ventricular arrhythmias.
Pulmonary Arterial Hypertension (PAH), a major cause of right ventricular failure, is associated with a high 5-year mortality rate. Arrhythmias account for a significant proportion of morbidity and mortality in PAH patients. Hence, there is a critical need for new therapies to effectively treat PAH-...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension that may be relevant for patients and caregivers.
- Circulation research Jan 29, 2026
Differential Impact of Recruited and Resident Macrophages on Hypoxia-Induced Pulmonary Hypertension.
Pulmonary interstitial macrophages can be divided into 2 distinct subsets with different origins: resident macrophages (resMФs) and recruited macrophages (recMФs). However, their specific roles in pulmonary arterial hypertension remain unclear. Bone marrow transplantation, the DT (diphth...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension that may be relevant for patients and caregivers.
- Hypertension (Dallas, Tex. : 1979) Jan 21, 2026
BMP9 Modulates IL-33 Signaling to Mitigate EndMT in Pulmonary Arterial Hypertension.
Pulmonary arterial hypertension (PAH) is a progressive disorder involving disrupted BMP (bone morphogenetic protein) signaling, pulmonary inflammation, and endothelial-to-mesenchymal transition (EndMT). We hypothesized that IL (interleukin)-33 signaling contributes to PAH progression by inducing End...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension that may be relevant for patients and caregivers.
- Journal of hepatology Jan 17, 2026
Early portopulmonary hypertension predicts mortality in patients with cirrhosis: Insights from the PORTO-DETECT cohort.
Portopulmonary hypertension (PoPH) is a severe complication of cirrhosis and portal hypertension. In 2022, a European task force revised the diagnostic criteria for pulmonary arterial hypertension (PAH), defining early stages as a mean pulmonary arterial pressure (mPAP) of 20.5-24.5 mmHg and pulmona...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension that may be relevant for patients and caregivers.
- The Annals of pharmacotherapy Dec 30, 2025
Sotatercept: A New Frontier in Pulmonary Arterial Hypertension Treatment.
To review the pharmacology, pharmacokinetics, safety, and efficacy of sotatercept for the management of pulmonary arterial hypertension (PAH). A literature search in PubMed, EMBASE, and the National Institutes of Health Clinical Trials Registry (http://www. gov) was conducted from January 2009 to Ju...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension that may be relevant for patients and caregivers.
- Biochemical pharmacology Dec 24, 2025
Agomelatine alleviates hypoxia-induced pulmonary arterial hypertension by activating mitophagy via the SIRT1/FoxO1/ULK1 signaling pathway.
Human melatonin receptor type 1/2 (MTR1/MTR2) are widely distributed throughout the body and play essential roles in regulating cardiovascular physiology. However, the therapeutic potential of agomelatine (AGM), a melatonin analog and nonselective MTR1/MTR2 agonist, in pulmonary arterial hypertensio...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension that may be relevant for patients and caregivers.
More on Pulmonary arterial hypertension
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.